Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
Merck & Co., Inc. (NYSE: MRK) has been upgraded to Buy by Deutsche Bank with a raised price target of $150, as the firm believes the market undervalues the company despite the looming Keytruda patent cliff. The analysis projects a clear path for growth beyond Keytruda, with a trough earnings “formation at hand.” Additionally, Merck announced FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ for treating specific platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, marking the first and only PD-1 inhibitors approved for this condition.